Foghorn Therapeutics (FHTX) Expected to Announce Earnings on Thursday

Key Points

• Foghorn Therapeutics is set to release its Q2 2025 earnings results on August 14th, with analysts predicting a loss of ($0.32) per share.
• In the previous quarter, Foghorn reported ($0.28) earnings per share, surpassing expectations and generating revenue of $7.56 million.
• Analysts currently maintain a consensus Buy rating for the company, with an average target price of $12.13.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. The business had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.62 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Stock Performance

Shares of FHTX opened at $4.90 on Thursday. The company has a market cap of $273.13 million, a price-to-earnings ratio of -4.12 and a beta of 3.05. The stock has a fifty day moving average price of $5.10 and a two-hundred day moving average price of $4.58. Foghorn Therapeutics has a 52-week low of $2.94 and a 52-week high of $10.25.

Institutional Trading of Foghorn Therapeutics

An institutional investor recently bought a new position in Foghorn Therapeutics stock. AQR Capital Management LLC purchased a new position in shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 18,693 shares of the company's stock, valued at approximately $68,000. Institutional investors and hedge funds own 61.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on FHTX. Citigroup began coverage on Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued an "outperform" rating for the company. JMP Securities restated a "market outperform" rating and issued a $9.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. HC Wainwright raised shares of Foghorn Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Finally, Citizens Jmp assumed coverage on shares of Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 target price on the stock. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Foghorn Therapeutics presently has a consensus rating of "Buy" and an average target price of $12.13.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.